Overview

The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery

Status:
Completed

Trial end date:
2014-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether IBI-10090 injection is effective in the treatment of inflammation associated with cataract surgery.

Phase:

Phase 3

Details

Lead Sponsor:

ICON Bioscience Inc